NovAccess Global IncOOTC XSNX Stock Report

NovAccess Global Inc. is a biopharmaceutical company. The Company is engaged in developing immunotherapies to treat brain tumor patients in the United States. It specializes in research related to utilizing a patient's own immune system to attack the cancer. The Company's technology is designed to combine a dendritic cell-based immunotherapeutic approach with a combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. TLR-AD1 is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. Its platform technology focuses on enhancing the patient's immune cells to fight their cancer by utilizing the antigens specific to the patient's tumor. It owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells.